RxDoctor Payments Data

Robert Lee, MD

Pulmonary Disease · Hackensack, NJNPI 1497830293

Payments from drug & device makers

$2,346in general payments, 2019–2025

Across 81 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$928
  • Merck$188
  • Boehringer Ingelheim$169
  • AstraZeneca$145
  • Amgen$130
  • Shionogi Inc$119
  • plus $667 from 17 others

What the payments were for

  • Food & beverage$2,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,346 in reported general payments places this provider in the 45th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$171,579
Medicare patients
306
Services billed
1,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$36,280
EliquisApixaban19$12,493
Breo ElliptaFluticasone/Vilanterol14$10,142
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,614
Albuterol Sulfate HfaAlbuterol Sulfate50$2,779
Montelukast Sodium17$274
Prednisone40$258
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$928$46,42252 claims
AstraZenecaBreztri Aerosphere$145$7,61412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →